temporal

A comprehensive resource available via ESMO OncologyPRO


A comprehensive resource developed by experts Prof. Simon Boulton, Prof. Charlie Gourley, Dr. Judith Balmaña and Dr. Violeta Serra, available via ESMO OncologyPRO portal, covering the following areas in detail:

  • Mechanism of Action (MoA) targeting DDR

  • MoA of PARP inhibitors (being the proof of concept for targeting DDR)

  • Clinical efficacy and safety/tolerability profile of PARP inhibitors and their benefit in various tumour types, now and in the future

  • Patient selection for PARP inhibition: diagnostics involved in DDR

  • Potential combination strategies with PARP inhibitors

  • Potential future applications for DDR

The information is primarily directed at healthcare professionals and contains information regarding the rationale for targeting DDR, including PARP inhibition as the proof of concept, the current role of PARP inhibition in clinical practice, and the potential future application of targeting DDR in clinical practice.

 

However, there is also a helpful section for patients and caregivers on the two novel types of targeted cancer drugs known as DDR (DNA damage response)-targeting agents and PARP (poly-ADP ribose polymerase) inhibitors with information on how these drugs work and how patients can work with their healthcare professional to manage any changes that may occur during treatment.

 

COR2ED have donated this content to ESMO to ensure that this comprehensive guide reflects today's best clinical practice in PARP inhibition and DNA Damage Response.

Prof. Simon Boulton has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Artios Pharma Ltd.

Dr Violeta Serra has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca and Tesaro. 

Dr Judith Balmaña has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca. 

Prof. Charlie Gourley has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Apera, Clovis, MSD, Nucana, Novartis, Roche, Sierra Oncology and Tesaro. 

Programme summary
  • clock Duration 30 MIN
  • clock Language(s) flag
Visit resource on ESMO OncologyPRO
Share this programme
This educational programme is supported by an Independent Medical Education Grant from AstraZeneca
I agree that this educational programme:

Was valuable to me

1/4

Other programmes of interest

Podcast
Oncology 
Colorectal cancer: understanding the needs of different patient populations

Exploring the impacts of age, ethnicity, socioeconomic status, and access to healthcare on patients with colorectal cancer

Experts
Prof. Tanios Bekaii-Saab, Deneen Richmond, Oncology Brothers (Moderators)
Endorsed by
COLONTOWN
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Podcast
Oncology 
Interpreting real-world evidence in later-line mCRC

Aligning real-world evidence with clinical trial data 

Experts
Prof. Tanios Bekaii-Saab, Prof. Shubham Pant
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Podcast

Episode

1

of 3

episode
Oncology 
Cáncer de próstata: Dificultades en la fase preanalítica y pruebas de biomarcadores (Spanish)

Moderado por los Oncology Brothers. Episodio 1 de una serie de podcast de video de 3 partes.

Experts
Dr Alexander Wyatt, Dr Petros Grivas, Oncology Brothers (Moderators)
Endorsed by
NASPCC AMP
  • download Downloadable
    Resources
  • clock 30 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Podcast

Episode

3

of 3

episode
Oncology 
Câncer de Ovário: Desafios da fase pré-analítica e teste de biomarcadores (Portuguese)

Moderado pelos Oncology Brothers. Episódio 3 da série de podcasts em vídeo de 3 partes

Experts
Assoc. Prof. Martina Murphy, Assoc. Prof. Caterina Marchiò, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 32 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Podcast

Episode

3

of 3

episode
Oncology 
Cáncer de ovario: Dificultades en la fase preanalítica y pruebas de biomarcadores (Spanish)

Moderado por los Oncology Brothers. Episodio 3 de una serie de podcast de 3 partes.

Experts
Assoc. Prof. Martina Murphy, Assoc. Prof. Caterina Marchiò, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 32 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Podcast

Episode

2

of 3

episode
Oncology 
Câncer de Pulmão: Desafios da fase pré-analítica e teste de biomarcadores (Portuguese)

Moderado pelos Oncology Brothers. Episódio 2 da série de podcasts em vídeo de 3 partes

Experts
Dr Bruna Pellini, Dr Semir Vranić, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar May 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.